UTMD Trades at a Premium to the Industry: How to Play the Stock? Debasmita Chatterjee Thu, October 8, 2026 at 1:02 PM EDT 4 min read UTMD +0.62% EOLS -1.29% CGC -4.96% ^GSPC -0.59% CGC -4.96% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
From a valuation perspective, Utah Medical Products, Inc. UTMD stock looks expensive. UTMD is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 4.05X, above the industry average of 2.68X. UTMD also trades at a higher valuation compared to other industry players, such as Evolus, Inc. EOLS and Canopy Growth Corporation CGC. Currently, EOLS and CGC trade at EV/sales multiples of 1.97X and 1.41X, respectively.
While this elevated valuation reflects investor confidence in the company's long-term potential, it also raises concerns about whether the stock can justify such lofty multiple. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.
Utah Medical's shares have gained 16.7% in the past year against the industry's 30.1% decline. The Zacks Medical sector has risen 4.1% while the S&P 500 has advanced 18%. Meanwhile, UTMD has outperformed CGC's 46.9% decline but underperformed Evolus' 24.2% rally in the same time frame.
Utah Medical's wholly owned subsidiary, Femcare Ltd., acquired Orion Medical Supplies in August 2026, providing an opportunity to expand its revenue base and improve operating efficiency. The acquired business is expected to contribute approximately $6 million in annual sales, supported by established demand for harm-reduction medical devices in the U.K. and Europe. Integrating Orion into Femcare's existing infrastructure should improve overhead absorption, while opportunities for geographic expansion could support long-term growth.
UTMD's strong financial position provides flexibility to pursue growth initiatives and shareholder returns. Cash and investments increased to $87.5 million as of June 30, 2026, from $85.8 million as of Dec. 31, 2025, while the company remained debt-free. Operating activities generated $4.5 million in cash during the first half of 2026. Its substantial liquidity supports investments in new technologies, potential acquisitions and product development without significant dependence on external financing.
UTMD continues to demonstrate resilient profitability despite softer revenues. Gross margin improved to 58.2% in the first half of 2026 from 56.6% in the year-ago period, reflecting a more favorable product mix and the absence of lower-margin sales to its former Chinese distributor. Operating margin remained healthy at 30.2%, while net margin stood at 30.7%. Its ability to sustain strong margins amid sales pressure highlights the underlying profitability of its specialized medical-device portfolio.
UTMD's product development initiatives and expanding biopharmaceutical customer base offer additional growth opportunities. Sales to domestic OEM customers excluding PendoTECH increased by $0.2 million in the first half of 2026, including $0.07 million from new biopharmaceutical customers. Management is targeting additional sales of high-pressure process-control transducer configurations to biopharmaceutical manufacturers. New product introductions and broader customer relationships could gradually offset lost business.
UTMD's consistent shareholder distributions reflect its cash-generating capabilities and disciplined capital allocation. In August 2026, the company announced a quarterly dividend of 31 cents per share, representing a 1.6% year-over-year increase. During the first half of 2026, UTMD distributed approximately $2 million in dividends and repurchased $0.2 million of common stock. Its substantial cash reserves and continued commitment to opportunistic buybacks support shareholder returns alongside future investments.
Utah Medical's revenues fell 12.3% to $17.3 million in the first half of 2026, primarily due to discontinued sales to two major customers. Slower-than-expected demand from new biopharma customers has further constrained recovery, prompting management to project a 10-13% revenue decline for 2026. Lower production volumes and elevated manufacturing overhead pressured profitability, with operating income declining 17.9% to $5.2 million. Filshie Clip System tariffs and rising raw material prices added cost pressures, while litigation expenses increased $0.3 million year over year.
UTMD's strong balance sheet, healthy margins, strategic acquisition and product development initiatives support its long-term growth prospects. However, near-term revenue pressures, customer losses and rising costs warrant caution.
Also, its valuation is higher than the industry average. For long-term investors, UTMD's strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Utah Medical Products, Inc. (UTMD): Free Stock Analysis Report
Canopy Growth Corporation (CGC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
